Silo Pharma Inc.

Company Overview

Business Model: Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics for underserved conditions, including Post-Traumatic Stress Disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. The company's strategy involves developing therapies that include both conventional drugs and psychedelic formulations. Its mission is to identify, license, and fund research for assets believed to be transformative for patient well-being and the healthcare industry.

Market Position: The company operates in a highly competitive industry characterized by emerging and innovative technologies, with competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and research organizations. Many competitors possess significantly greater financial, technical, and human resources. Silo Pharma, Inc. focuses on developing therapies for unmet needs in areas such as depression, PTSD, and rare neurological disorders, leveraging intellectual property and technology rights from leading universities and researchers. The company's product candidates, particularly those involving psilocybin and ketamine, target conditions with a large unmet medical need.

Recent Strategic Developments:

• SPC-15 (PTSD and Anxiety): Submitted a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the U.S. Food and Drug Administration (FDA) in June 2024. Held a pre-IND meeting with the FDA in September 2024 to align on the 505(b)(2) regulatory pathway. Currently conducting GLP-compliant pharmacokinetic and pharmacodynamic studies, with first dosing completed in an IND-enabling GLP-compliant toxicology and toxicokinetics study in March 2025, aiming for an IND submission in 2025. Silo Pharma, Inc. holds exclusive global rights to develop and commercialize SPC-15 through an exclusive license agreement with Columbia University (effective July 1, 2024) and utilizes Medspray Pharma BV's proprietary soft mist nasal spray technology for delivery (effective October 31, 2023).
• SP-26 (Fibromyalgia and Chronic Pain): Filed a provisional patent application with the USPTO in March 2023. Currently in preclinical research, with initial animal studies evaluating dosage, time release, and absorption beginning in early 2025. Intends to follow the FDA's 505(b)(2) regulatory pathway.
• SPC-14 (Alzheimer’s Disease): Developed under a sponsored research agreement with Columbia University. Silo Pharma, Inc. has exclusive global rights to develop and commercialize SPC-14 (effective July 1, 2024). The sponsored research agreement with Columbia University was extended in October 2022 to conduct further research into SPC-14's mechanism of action.
• SPU-16 (CNS Disorders, Multiple Sclerosis): Holds an exclusive, worldwide, sublicensable, royalty-bearing license from the University of Maryland, Baltimore (UMB) (effective February 12, 2021) for intellectual property related to CNS-homing peptides. A U.S. patent (US 11,766,403, B2) for "Peptide-Targeted Liposomal Delivery For Treatment, Diagnosis, and Imaging of Diseases and Disorders" was issued in April 2023 under this license.

Geographic Footprint: Silo Pharma, Inc.'s principal executive offices are located in Sarasota, FL. The company holds exclusive worldwide licenses for its product candidates, indicating a global development and commercialization strategy. Revenue is generated from a single licensee, Aikido Pharma Inc., but no specific geographic breakdown of this revenue is provided.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 91.9%
• Operating Margin: -6526.4%
• Net Margin: -6092.6%

Investment in Growth:

• R&D Expenditure: $2,368,156 (3284.5% of revenue)
• Capital Expenditures: Not explicitly disclosed as a separate line item for property and equipment. Intangible assets, primarily an exclusive license agreement, increased by $241,215 in 2024.
• Strategic Investments: The company made aggregate payments for the purchase of short-term investments of $175,543 in 2024 and $4,147,107 in 2023.

Business Segment Analysis

Silo Pharma, Inc. operates as a single operating segment, focusing on the development of novel biopharmaceutical therapeutics. Therefore, a detailed breakdown by business segment is not applicable.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $173,113 in 2024 (102,855 shares) and $471,121 in 2023 (252,855 shares). In aggregate, 355,710 shares were repurchased for a total cost of $644,234 and subsequently cancelled in 2024.
• Dividend Payments: Silo Pharma, Inc. has never declared or paid cash dividends and does not expect to do so in the foreseeable future.
• Dividend Yield: 0%
• Future Capital Return Commitments: The stock repurchase program, initially authorized for up to $1.0 million, was extended multiple times, with the latest extension to April 30, 2024.

Balance Sheet Position:

• Cash and Equivalents: $3,905,799 (as of December 31, 2024)
• Total Debt: Not explicitly disclosed as traditional long-term debt. Current liabilities primarily consist of accounts payable and accrued expenses ($1,583,895) and current deferred revenue ($72,102). Long-term liabilities consist of deferred revenue ($721,578).
• Net Cash Position: $3,905,799 (assuming no traditional debt)

Cash Flow Generation:

• Operating Cash Flow: $(3,833,914) (2024)
• Free Cash Flow: Not explicitly provided. Given the developmental stage and lack of traditional capital expenditures on property and equipment, operating cash flow is the primary indicator of cash generation/usage from core activities.

Operational Excellence

Production & Service Model: As a developmental stage biopharmaceutical company, Silo Pharma, Inc. relies on third-party vendors, contract research organizations (CROs), and contract manufacturers for its research, development, testing, and potential manufacturing activities. The company's operational philosophy is centered on acquiring and developing intellectual property and technology rights from leading universities and researchers.

Supply Chain Architecture: Key Suppliers & Partners:

• Research & Development Partners: Columbia University (for SPC-15 and SPC-14 research and licensing), University of Maryland, Baltimore (UMB) (for SPU-16 research and licensing).
• Technology Partners: Medspray Pharma BV (for proprietary soft mist nasal spray technology for SPC-15 delivery).
• Manufacturing Partners: Not explicitly named, but the company anticipates using contract manufacturers for future product development.

Facility Network:

• Manufacturing: Not directly owned or operated; expected to be outsourced to contract manufacturers.
• Research & Development: Conducted through sponsored research agreements with academic institutions like Columbia University and the University of Maryland, Baltimore.
• Distribution: Not yet established, as no products are approved for commercial sale.
• Principal Executive Offices: Located at 677 N. Washington Boulevard Sarasota, FL, rented on a month-to-month basis for approximately $80 per month.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Not yet established, as no products are approved for commercial sale.
• Channel Partners: The company has a license and sublicense agreement with Aikido Pharma Inc., which accounts for 100% of its current revenue from customer license fees. This suggests a partnership-driven approach for commercialization.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Aikido Pharma Inc. is the sole licensee, accounting for 100% of total revenues from customer license fees for the years ended December 31, 2024 and 2023.
• Customer Concentration: 100% revenue concentration from one licensee (Aikido Pharma Inc.) poses a significant concentration risk.

Geographic Revenue Distribution: Not explicitly disclosed beyond the worldwide licenses granted to Aikido Pharma Inc.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry, particularly in the rare disease therapeutics and psychedelic medicine segments, is characterized by many newly emerging and innovative technologies, intense competition, and a strong emphasis on proprietary product rights. The use of psychedelics for medicinal purposes is a relatively new and highly regulated market, with increasing efforts in the discovery of new psychedelic compounds.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Silo Pharma, Inc. faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and medical research organizations. Many of these competitors have established markets, substantially greater financial, technical, human, and other resources, and more experience in clinical trials and regulatory approvals. Emerging Competitive Threats: An increasing number of companies are entering the field of psychedelic compound discovery. The emergence of clinics without proper therapeutic infrastructure or adequate clinical research in the legalized psilocybin market could pose reputational and regulatory risks to the industry.

Competitive Response Strategy: Silo Pharma, Inc.'s strategy involves acquiring and developing intellectual property and technology rights from leading universities and researchers, focusing on novel therapies and leveraging proprietary delivery mechanisms (e.g., Medspray's intranasal technology) to gain a competitive advantage through increased brain drug concentration, faster onset, and optimized safety.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Limited Operating History: Silo Pharma, Inc. has a limited operating history under its current business plan (since September 2020) and no history of profitable operations, making evaluation of future prospects difficult.
• Psychedelics Industry Risks: The psychedelics industry and market are relatively new, highly regulated, and may not succeed in the long term. Public perception and potential misuse of psychedelics could negatively impact market acceptance and regulatory approval.
• Central Nervous System Drug Development: Research and development of drugs targeting the central nervous system is particularly difficult, time-consuming, and has a higher failure rate, making it hard to predict drug effects and patient responses.
• Market Acceptance: Future commercial success depends on market access and acceptance by healthcare professionals, patients, healthcare payors, and the medical community, which may be influenced by negative public perceptions and the need for significant educational resources.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Dependency: Reliance on third-party vendors, CROs, and contract manufacturers for research, development, testing, and manufacturing exposes the company to risks of delays, quality control issues, and compliance failures.
• Clinical Trial Delays: Clinical drug development is lengthy, expensive, and uncertain. Delays in initiating or completing clinical trials, unforeseen events, or difficulties in patient enrollment could prevent or delay regulatory approvals and commercialization.
• Regulatory Compliance: Failure to comply with extensive U.S. and foreign laws and regulations governing controlled substances (e.g., DEA, FDA), healthcare fraud and abuse, and data protection could result in substantial penalties, interruptions to development, and adverse effects on business operations.

Financial & Regulatory Risks

Market & Financial Risks:

• Need for Additional Financing: Silo Pharma, Inc. will require additional financing to fund operations and execute its business plan. Inability to raise capital on acceptable terms could lead to delays or discontinuation of operations.
• Dilution Risk: Raising additional capital through equity offerings or convertible debt could dilute existing stockholders' ownership interests.
• Product Liability Claims: Exposure to potential product liability and professional indemnity risks inherent in therapeutic substance development, manufacturing, and use, with insurance potentially not covering all damages.
• Healthcare Reform: Enacted and future legislation (e.g., ACA, Inflation Reduction Act of 2022) may increase the difficulty and cost of obtaining marketing approval and commercializing therapeutics, impacting pricing and reimbursement.
• Reimbursement Uncertainty: The successful commercialization of future therapeutic candidates depends on adequate reimbursement levels and pricing policies from governmental authorities and health insurers, which is uncertain for newly approved therapies, especially controlled substances.

Regulatory & Compliance Risks:

• Controlled Substance Regulations: Product candidates containing psilocybin (Schedule I) and ketamine (Schedule III) are subject to stringent DEA regulations, including registration, security, recordkeeping, reporting, storage, manufacturing, distribution, and importation requirements. Rescheduling of psilocybin by the DEA is necessary for commercial marketing, which is dependent on FDA approval and recommendation. State laws also impose separate controlled substance regulations.
• Data Privacy & Security: Compliance with U.S. federal and state health and data protection laws (e.g., HIPAA) is critical. Failure to protect against service interruptions, data corruption, cyber-attacks, or network security breaches could disrupt operations, lead to unauthorized access, and result in significant legal and financial exposure.
• Government Funding Changes: Disruptions or changes in funding for the FDA and other government agencies could hinder their ability to review and approve new products in a timely manner.

Innovation & Technology Leadership

Research & Development Focus: Silo Pharma, Inc. is a developmental stage biopharmaceutical company with a core focus on novel therapeutics for underserved conditions. Core Technology Areas:

• Serotonin 4 (5-HT4) Receptor Agonism: Lead product candidate SPC-15 targets 5-HT4 receptors for PTSD and stress-induced anxiety disorders.
• Ketamine-based Formulations: SP-26 is a time-release ketamine-based injectable dissolvable polymer implant for fibromyalgia and chronic pain relief. SPC-14 involves ketamine in combination with other drugs for Alzheimer’s disease and depression.
• CNS-Homing Peptides: SPU-16 utilizes homing peptides for targeted drug delivery to the central nervous system, with an initial indication for multiple sclerosis, aiming to reduce toxicity and enhance therapeutic payload delivery.
• Intranasal Drug Delivery: SPC-15 leverages proprietary soft mist nasal spray technology for nose-to-brain drug dispersion, aiming for faster onset and optimized safety.

Innovation Pipeline:

• SPC-15: In preclinical development, aiming for IND submission in 2025, with potential additional applications for eating disorders and anorexia, and enhanced efficacy when combined with an NMDA receptor antagonist for major depressive disorder.
• SP-26: In preclinical research, with initial animal studies evaluating dosage, time release, and absorption.
• SPC-14: In preclinical research, with ongoing studies into its mechanism of action for Alzheimer’s disease.
• SPU-16: In preclinical research for CNS disorders, initially targeting multiple sclerosis.

Intellectual Property Portfolio:

• Patent Strategy: Silo Pharma, Inc. actively seeks broad intellectual property protection through patents and contractual arrangements. The company's portfolio includes 5 issued patents and 20 pending patent applications across 14 patent families in the U.S. and abroad.
• Patent Holdings:
  • Owned IP: Five pending U.S. patent applications related to CNS-homing peptides for delivering compounds (e.g., NSAIDs, psilocybin) for diseases like arthritis, CNS diseases, neurological diseases, and cancer.
  • Licensed IP (University of Maryland, Baltimore): One issued U.S. patent covering certain CNS homing peptides and their uses, and one issued U.S. patent covering peptides selectively targeting inflamed synovial tissue.
  • Licensed IP (Columbia University): Three issued U.S. patents related to the treatment or prevention of stress-induced affective disorders or stress-induced psychopathology.
• IP Litigation: The company may become involved in lawsuits to protect or enforce its intellectual property rights, which could be expensive and time-consuming.

Technology Partnerships:

• Strategic Alliances: Exclusive license agreements with Columbia University for SPC-15 and SPC-14, and with the University of Maryland, Baltimore for SPU-16.
• Research Collaborations: Sponsored research agreements with Columbia University (for ketamine in Alzheimer’s and depression) and the University of Maryland, Baltimore (for targeted liposomal drug delivery for rheumatoid arthritis).
• Delivery Technology Partnerships: Exclusive license agreement with Medspray Pharma BV for its soft mist nasal spray technology.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success is materially dependent on the expertise and continued service of its management and key personnel, including Eric Weisblum. The company aims to attract and retain highly qualified management and employees.

Board Composition: The board of directors consists of four members: Eric Weisblum (Chairman, CEO, President, and Director), Wayne D. Linsley (Director), Dr. Kevin Muñoz (Director), and Jeff Pavell (Director). All directors, except Eric Weisblum, are considered independent. The board has standing Audit and Compensation committees, with all members of these committees being independent. The Nominating and Corporate Governance Committee also consists of independent directors.

Human Capital Strategy

Workforce Composition:

• Total Employees: 3 full-time employees (as of March 26, 2025).
• Geographic Distribution: Not explicitly detailed, but principal executive offices are in Sarasota, FL.
• Skill Mix: Not explicitly detailed, but implies a focus on biopharmaceutical research and development expertise, supported by management and administrative functions.

Talent Management: Acquisition & Retention: The company's future success depends on its ability to attract and retain highly qualified management personnel and other employees. Compensation policies are designed to attract and retain superior talent and reward individual performance.

Regulatory Environment & Compliance

Regulatory Framework: Silo Pharma, Inc. operates in a highly regulated environment, subject to extensive oversight by the FDA and other regulatory authorities at federal, state, local, and foreign levels. This regulation covers all aspects of drug development, from research and testing to manufacturing, quality control, approval, marketing, and post-approval monitoring. Industry-Specific Regulations:

• Drug Development & Approval: The company must navigate complex preclinical, clinical, manufacturing, and commercial approval requirements. This includes adherence to good laboratory practice (GLP), current good manufacturing practice (cGMP), and good clinical practice (GCP) requirements. The FDA approval process involves multiple stages, including IND applications, clinical trials, and New Drug Application (NDA) submissions.
• Controlled Substances Act (CSA): Product candidates containing psilocybin (Schedule I) and ketamine (Schedule III) are subject to stringent DEA regulations, including registration, security, recordkeeping, reporting, storage, manufacturing, distribution, and importation requirements. Rescheduling of psilocybin by the DEA is necessary for commercial marketing, which is dependent on FDA approval and recommendation. State laws also impose separate controlled substance regulations.
• Healthcare Fraud & Abuse Laws: Future operations, particularly relationships with healthcare professionals and payors, will be subject to U.S. federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act) and health information privacy and security laws (e.g., HIPAA). Non-compliance could lead to substantial penalties.

Legal Proceedings: Silo Pharma, Inc. is not currently aware of any legal proceedings or claims that will have a material adverse effect on its business, financial condition, or operating results.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company's provision for income taxes was $0 for both 2024 and 2023.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2024, the company had significant NOL carryforwards. A full valuation allowance has been established against the net deferred tax asset due to the uncertainty of realizing future taxable income, resulting in no recognized deferred tax asset. NOLs from 2018 onwards can be carried over indefinitely, subject to annual usage limits.

Insurance & Risk Transfer

Risk Management Framework: The Board of Directors oversees management’s processes for identifying and mitigating risks, including cybersecurity risks, to align risk exposure with strategic objectives. Senior leadership and a cybersecurity consultant regularly brief the Board on cybersecurity posture. Insurance Coverage: Silo Pharma, Inc. maintains cybersecurity insurance. However, the company notes that costs related to cybersecurity threats or disruptions may not be fully insured. The company is also exposed to potential product liability and professional indemnity risks, but the adequacy of product liability insurance is not explicitly detailed.